Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-05

AUTHORS

Marc C. Chamberlain, Sandra K. Johnston

ABSTRACT

Primary spinal cord tumors constitute 2-4% of all primary central nervous system malignancies in adults of which less than 5% are glioblastoma. A retrospective evaluation to determine toxicity and response to bevacizumab in patients with recurrent spinal cord glioblastoma. Six patients (4 males; 2 females: median age 34 years) with recurrent spinal cord glioblastoma were treated with bevacizumab (10 mg/kg given once every 2 weeks wherein 2 treatments constituted a cycle of therapy). All patients had failed surgery and temozolomide-based chemoradiotherapy and post-radiotherapy temozolomide. Blood counts, chemistry panel, urine protein to creatinine ratio and neurologic examination were obtained bi-weekly. Contrast-enhanced spine MRI was performed after one cycle of therapy and thereafter following every two cycles of bevacizumab. Treatment-related complications included fatigue in six patients, constipation in 4, hypertension in 2, venous thrombosis in 2, and infection without neutropenia in 2. There were three grade 3 toxicities (1 each fatigue, leukopenia and venous thrombosis). There were no treatment-related deaths. After one cycle of bevacizumab, one patient (17%) demonstrated progressive disease, 2 (34%) partial responses and three (51%) stable disease. Overall median response or stable disease duration (disease free progression) was 7 months (range 3-11 months). Overall median survival was 9 months (range of 5-13 months). Bevacizumab is well tolerated, has tolerable toxicity and apparent activity in this small cohort of adults with recurrent spinal cord glioblastoma. More... »

PAGES

427-432

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-010-0330-6

DOI

http://dx.doi.org/10.1007/s11060-010-0330-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1019036958

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20680397


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioblastoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Magnetic Resonance Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Spinal Cord Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Seattle Cancer Care Alliance", 
          "id": "https://www.grid.ac/institutes/grid.430269.a", 
          "name": [
            "Departments of Neurology and Neurological Surgery, Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer Research Institute, 825 Eastlake Ave E, POB 19023, MS G4940, 98109-1023, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chamberlain", 
        "givenName": "Marc C.", 
        "id": "sg:person.01326261166.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Seattle Cancer Care Alliance", 
          "id": "https://www.grid.ac/institutes/grid.430269.a", 
          "name": [
            "Departments of Neurology and Neurological Surgery, Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer Research Institute, 825 Eastlake Ave E, POB 19023, MS G4940, 98109-1023, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johnston", 
        "givenName": "Sandra K.", 
        "id": "sg:person.01122114252.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122114252.85"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/cncr.23677", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003118803"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.3055", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010751135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-006-9241-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015983460", 
          "https://doi.org/10.1007/s11060-006-9241-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0360-3016(00)00690-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025413076"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1006470523052", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027846301", 
          "https://doi.org/10.1023/a:1006470523052"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.26.9027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029960724"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.22.1515", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034731213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0303-8467(96)00555-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041593830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.8721", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042965400"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.26.3541", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043187529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1010680924975", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043464068", 
          "https://doi.org/10.1023/a:1010680924975"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2008.04.060", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048141455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa043330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052112015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1989.71.6.0842", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071095581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1989.71.6.0842", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071095581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1989.71.6.0842", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071095581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1998.88.2.0215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071098674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1998.88.2.0215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071098674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1998.88.2.0215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071098674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1227/01.neu.0000158318.66568.cc", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077044204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1990.8.7.1277", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078716995"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-05", 
    "datePublishedReg": "2011-05-01", 
    "description": "Primary spinal cord tumors constitute 2-4% of all primary central nervous system malignancies in adults of which less than 5% are glioblastoma. A retrospective evaluation to determine toxicity and response to bevacizumab in patients with recurrent spinal cord glioblastoma. Six patients (4 males; 2 females: median age 34 years) with recurrent spinal cord glioblastoma were treated with bevacizumab (10 mg/kg given once every 2 weeks wherein 2 treatments constituted a cycle of therapy). All patients had failed surgery and temozolomide-based chemoradiotherapy and post-radiotherapy temozolomide. Blood counts, chemistry panel, urine protein to creatinine ratio and neurologic examination were obtained bi-weekly. Contrast-enhanced spine MRI was performed after one cycle of therapy and thereafter following every two cycles of bevacizumab. Treatment-related complications included fatigue in six patients, constipation in 4, hypertension in 2, venous thrombosis in 2, and infection without neutropenia in 2. There were three grade 3 toxicities (1 each fatigue, leukopenia and venous thrombosis). There were no treatment-related deaths. After one cycle of bevacizumab, one patient (17%) demonstrated progressive disease, 2 (34%) partial responses and three (51%) stable disease. Overall median response or stable disease duration (disease free progression) was 7 months (range 3-11 months). Overall median survival was 9 months (range of 5-13 months). Bevacizumab is well tolerated, has tolerable toxicity and apparent activity in this small cohort of adults with recurrent spinal cord glioblastoma.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11060-010-0330-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "102"
      }
    ], 
    "name": "Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab", 
    "pagination": "427-432", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "5ab466f50dd4a95ff7a22a02a00eb3d98196236a9db8e6230a41c89fd6aefd6e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20680397"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309335"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-010-0330-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1019036958"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-010-0330-6", 
      "https://app.dimensions.ai/details/publication/pub.1019036958"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000531.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs11060-010-0330-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-010-0330-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-010-0330-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-010-0330-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-010-0330-6'


 

This table displays all metadata directly associated to this object as RDF triples.

198 TRIPLES      21 PREDICATES      63 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-010-0330-6 schema:about N29b9a41f864a40da90e9efca3a5f86fa
2 N3dcf104c1d014ccaabaa4f8dd7ef5ddd
3 N3fbe8741c04947f8b1340230c77cb938
4 N4745cf84d87b41618e08be9184fa2efc
5 N4b0ed87bc062471aa1f5f9864eb0e58e
6 N66edcecb7e67430090570460ff719e14
7 N68d926f94feb491c8800ce037439e5bf
8 N790b4da6a8b54bc498d3e8f41def927a
9 Na9ed94dc2016494d9404fd5f8b65375a
10 Naab7c157e824401c9b5b160aebd1a696
11 Nbdbf44388a31414a8e19e08c6f4f2de0
12 Nc61cdbe086ba41408378f3d0e373ac9e
13 Nce9f7ad4065944b0add22b1d47cbd5b8
14 Nd685dcbcd2724b71adb7e2ebbad2499a
15 Ne2f78a44ae584c3e970a53e6569d7b1e
16 Nf3cceef070534784b0fd075bae1976d2
17 Nfe1da1416eeb4e2c8f18b6770844899b
18 anzsrc-for:11
19 anzsrc-for:1109
20 schema:author Nd182721460dc459da7dafc9f8040b999
21 schema:citation sg:pub.10.1007/s11060-006-9241-y
22 sg:pub.10.1023/a:1006470523052
23 sg:pub.10.1023/a:1010680924975
24 https://doi.org/10.1002/cncr.23677
25 https://doi.org/10.1016/j.ijrobp.2008.04.060
26 https://doi.org/10.1016/s0303-8467(96)00555-0
27 https://doi.org/10.1016/s0360-3016(00)00690-8
28 https://doi.org/10.1056/nejmoa043330
29 https://doi.org/10.1200/jco.1990.8.7.1277
30 https://doi.org/10.1200/jco.2008.16.3055
31 https://doi.org/10.1200/jco.2008.19.8721
32 https://doi.org/10.1200/jco.2009.22.1515
33 https://doi.org/10.1200/jco.2009.26.3541
34 https://doi.org/10.1200/jco.2009.26.9027
35 https://doi.org/10.1227/01.neu.0000158318.66568.cc
36 https://doi.org/10.3171/jns.1989.71.6.0842
37 https://doi.org/10.3171/jns.1998.88.2.0215
38 schema:datePublished 2011-05
39 schema:datePublishedReg 2011-05-01
40 schema:description Primary spinal cord tumors constitute 2-4% of all primary central nervous system malignancies in adults of which less than 5% are glioblastoma. A retrospective evaluation to determine toxicity and response to bevacizumab in patients with recurrent spinal cord glioblastoma. Six patients (4 males; 2 females: median age 34 years) with recurrent spinal cord glioblastoma were treated with bevacizumab (10 mg/kg given once every 2 weeks wherein 2 treatments constituted a cycle of therapy). All patients had failed surgery and temozolomide-based chemoradiotherapy and post-radiotherapy temozolomide. Blood counts, chemistry panel, urine protein to creatinine ratio and neurologic examination were obtained bi-weekly. Contrast-enhanced spine MRI was performed after one cycle of therapy and thereafter following every two cycles of bevacizumab. Treatment-related complications included fatigue in six patients, constipation in 4, hypertension in 2, venous thrombosis in 2, and infection without neutropenia in 2. There were three grade 3 toxicities (1 each fatigue, leukopenia and venous thrombosis). There were no treatment-related deaths. After one cycle of bevacizumab, one patient (17%) demonstrated progressive disease, 2 (34%) partial responses and three (51%) stable disease. Overall median response or stable disease duration (disease free progression) was 7 months (range 3-11 months). Overall median survival was 9 months (range of 5-13 months). Bevacizumab is well tolerated, has tolerable toxicity and apparent activity in this small cohort of adults with recurrent spinal cord glioblastoma.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree false
44 schema:isPartOf N511d620c695f4d34ba580ea5266d3f67
45 N54ea989807694705a867e0bf7eaed263
46 sg:journal.1094205
47 schema:name Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab
48 schema:pagination 427-432
49 schema:productId N258a63be738742e3b45227fb26e0e474
50 N5ee49260a62c4cbcb3323ce27d605818
51 N897e22491dd64028b03d3fadc1381cb7
52 Nbcb5c99a312b444694e2cd8cb3231005
53 Nc94f2788518340279c47191736657916
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019036958
55 https://doi.org/10.1007/s11060-010-0330-6
56 schema:sdDatePublished 2019-04-11T00:20
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher Na10e4b6da12847fbb7e09f494cb16d13
59 schema:url http://link.springer.com/10.1007%2Fs11060-010-0330-6
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N1ded34060d2d4481a3e5abae33de7f00 rdf:first sg:person.01122114252.85
64 rdf:rest rdf:nil
65 N258a63be738742e3b45227fb26e0e474 schema:name readcube_id
66 schema:value 5ab466f50dd4a95ff7a22a02a00eb3d98196236a9db8e6230a41c89fd6aefd6e
67 rdf:type schema:PropertyValue
68 N29b9a41f864a40da90e9efca3a5f86fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Adult
70 rdf:type schema:DefinedTerm
71 N3dcf104c1d014ccaabaa4f8dd7ef5ddd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Spinal Cord Neoplasms
73 rdf:type schema:DefinedTerm
74 N3fbe8741c04947f8b1340230c77cb938 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Retrospective Studies
76 rdf:type schema:DefinedTerm
77 N4745cf84d87b41618e08be9184fa2efc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Antibodies, Monoclonal
79 rdf:type schema:DefinedTerm
80 N4b0ed87bc062471aa1f5f9864eb0e58e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Neoplasm Recurrence, Local
82 rdf:type schema:DefinedTerm
83 N511d620c695f4d34ba580ea5266d3f67 schema:volumeNumber 102
84 rdf:type schema:PublicationVolume
85 N54ea989807694705a867e0bf7eaed263 schema:issueNumber 3
86 rdf:type schema:PublicationIssue
87 N5ee49260a62c4cbcb3323ce27d605818 schema:name nlm_unique_id
88 schema:value 8309335
89 rdf:type schema:PropertyValue
90 N66edcecb7e67430090570460ff719e14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Humans
92 rdf:type schema:DefinedTerm
93 N68d926f94feb491c8800ce037439e5bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Middle Aged
95 rdf:type schema:DefinedTerm
96 N790b4da6a8b54bc498d3e8f41def927a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Treatment Outcome
98 rdf:type schema:DefinedTerm
99 N897e22491dd64028b03d3fadc1381cb7 schema:name doi
100 schema:value 10.1007/s11060-010-0330-6
101 rdf:type schema:PropertyValue
102 Na10e4b6da12847fbb7e09f494cb16d13 schema:name Springer Nature - SN SciGraph project
103 rdf:type schema:Organization
104 Na9ed94dc2016494d9404fd5f8b65375a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Angiogenesis Inhibitors
106 rdf:type schema:DefinedTerm
107 Naab7c157e824401c9b5b160aebd1a696 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Magnetic Resonance Imaging
109 rdf:type schema:DefinedTerm
110 Nbcb5c99a312b444694e2cd8cb3231005 schema:name pubmed_id
111 schema:value 20680397
112 rdf:type schema:PropertyValue
113 Nbdbf44388a31414a8e19e08c6f4f2de0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Female
115 rdf:type schema:DefinedTerm
116 Nc61cdbe086ba41408378f3d0e373ac9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Glioblastoma
118 rdf:type schema:DefinedTerm
119 Nc94f2788518340279c47191736657916 schema:name dimensions_id
120 schema:value pub.1019036958
121 rdf:type schema:PropertyValue
122 Nce9f7ad4065944b0add22b1d47cbd5b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Salvage Therapy
124 rdf:type schema:DefinedTerm
125 Nd182721460dc459da7dafc9f8040b999 rdf:first sg:person.01326261166.36
126 rdf:rest N1ded34060d2d4481a3e5abae33de7f00
127 Nd685dcbcd2724b71adb7e2ebbad2499a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Male
129 rdf:type schema:DefinedTerm
130 Ne2f78a44ae584c3e970a53e6569d7b1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Antibodies, Monoclonal, Humanized
132 rdf:type schema:DefinedTerm
133 Nf3cceef070534784b0fd075bae1976d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Bevacizumab
135 rdf:type schema:DefinedTerm
136 Nfe1da1416eeb4e2c8f18b6770844899b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Young Adult
138 rdf:type schema:DefinedTerm
139 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
140 schema:name Medical and Health Sciences
141 rdf:type schema:DefinedTerm
142 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
143 schema:name Neurosciences
144 rdf:type schema:DefinedTerm
145 sg:journal.1094205 schema:issn 0167-594X
146 1573-7373
147 schema:name Journal of Neuro-Oncology
148 rdf:type schema:Periodical
149 sg:person.01122114252.85 schema:affiliation https://www.grid.ac/institutes/grid.430269.a
150 schema:familyName Johnston
151 schema:givenName Sandra K.
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122114252.85
153 rdf:type schema:Person
154 sg:person.01326261166.36 schema:affiliation https://www.grid.ac/institutes/grid.430269.a
155 schema:familyName Chamberlain
156 schema:givenName Marc C.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36
158 rdf:type schema:Person
159 sg:pub.10.1007/s11060-006-9241-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1015983460
160 https://doi.org/10.1007/s11060-006-9241-y
161 rdf:type schema:CreativeWork
162 sg:pub.10.1023/a:1006470523052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027846301
163 https://doi.org/10.1023/a:1006470523052
164 rdf:type schema:CreativeWork
165 sg:pub.10.1023/a:1010680924975 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043464068
166 https://doi.org/10.1023/a:1010680924975
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1002/cncr.23677 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003118803
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/j.ijrobp.2008.04.060 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048141455
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/s0303-8467(96)00555-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041593830
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/s0360-3016(00)00690-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025413076
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1056/nejmoa043330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052112015
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1200/jco.1990.8.7.1277 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078716995
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1200/jco.2008.16.3055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010751135
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1200/jco.2008.19.8721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042965400
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1200/jco.2009.22.1515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034731213
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1200/jco.2009.26.3541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043187529
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1200/jco.2009.26.9027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029960724
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1227/01.neu.0000158318.66568.cc schema:sameAs https://app.dimensions.ai/details/publication/pub.1077044204
191 rdf:type schema:CreativeWork
192 https://doi.org/10.3171/jns.1989.71.6.0842 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071095581
193 rdf:type schema:CreativeWork
194 https://doi.org/10.3171/jns.1998.88.2.0215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071098674
195 rdf:type schema:CreativeWork
196 https://www.grid.ac/institutes/grid.430269.a schema:alternateName Seattle Cancer Care Alliance
197 schema:name Departments of Neurology and Neurological Surgery, Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer Research Institute, 825 Eastlake Ave E, POB 19023, MS G4940, 98109-1023, Seattle, WA, USA
198 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...